I. Raber, S. Warack, J. Kanduri, et. al.
Oncologist. 2020 Mar;25(3):e606-e609. doi: 10.1634/theoncologist.2019-0762
CARDIONCOLOGY.ORG ABSTRACT:
This study assesses cardiotoxicity in patients who received fluoropyrimidines, chemotherapeutic agents that have been associated with coronary vasospasm, with control patients.
The results indicate that fluoropyrimidine use tended to increase cardiotoxicity in patients compared to controls who did not receive the drug. Furthermore, cardiovascular disease was not limited to coronary vasospasm, but also with other cardiac risk factors as well as ischemic heart disease.
© All Rights Reserved